in4thelonghaul

Does Immunomedics' Success Mean Human Genome Sciences' Failure?

HGSI's drop was primarily a market reaction to news that the GSK buyout rumor was false...apparently per GSK statement indicating they were not in active negotiations with HGSI.

IMMU is roughly 2 years behind HGSI, and is yet to achieve positive P-3 results...a very very big difference from success in a P-2 trial.

BTW, HGSI also has a healthy pipeline, including a treatment for Hep-C and a treatment for post-inhalation anthrax exposure...a very tough nut to crack, which the U.S. government has placed 2 orders for; the operative word here is "post" as in after exposure. Trial results indicate this anthrax treatment, called ABthrax, likely allows roughly a 50% chance of survival for an indication which is usually fatal.

At this point...IMMU presents no threat to HGSI.